Tezepelumab for severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 80 years old.
- A doctor has diagnosed you with asthma, and you have had at least one severe asthma attack in the past year that needed treatment with steroid pills or a hospital visit.
- You are currently taking a high-dose inhaled steroid combined with a long-acting bronchodilator (like Symbicort, Advair, or Breo) every day.
- You do not have other lung diseases like COPD, bronchiectasis, or pulmonary fibrosis.
- You are not a current smoker, and if you used to smoke, you quit at least 6 months ago and smoked fewer than 10 pack-years (e.g., 1 pack a day for 10 years).
- You are willing to use effective birth control (if female and able to have children) and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called Tezepelumab can help adults with asthma who visit the emergency room. It aims to reduce severe asthma attacks and improve breathing control.
This study looks at whether tezepelumab, a biologic medication, can help people with allergic bronchopulmonary aspergillosis (ABPA) and severe asthma. It aims to reduce asthma attacks and improve breathing.
This study tests whether a physical activity program can help people with severe asthma achieve better control and reduce flare-ups when added to a new treatment called tezepelumab.
This trial looks at whether people with severe asthma who are taking the biologic tezepelumab can safely reduce their use of inhaled corticosteroids (ICS). It aims to see if reducing or stopping ICS affects asthma symptoms or flare-ups.
This trial tests whether adding an allergy immunotherapy tablet (which helps your immune system get used to dust mites) to a biologic treatment (tezepelumab, which reduces airway inflammation) can keep severe asthma under control better than the biologic alone. It may help reduce asthma attacks and improve daily symptoms.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.